Recommendations for Management of Clinically Significant Drug-Drug Interactions With Statins and Select Agents Used in Patients With Cardiovascular Disease: A Scientific Statement From the American Heart Association

  title={Recommendations for Management of Clinically Significant Drug-Drug Interactions With Statins and Select Agents Used in Patients With Cardiovascular Disease: A Scientific Statement From the American Heart Association},
  author={Barbara S. Wiggins and Joseph J. Saseen and Robert Lee Page and Brent N. Reed and Kevin B. Sneed and John B. Kostis and David E. Lanfear and Salim S. Virani and Pamela Bowe Morris},
A drug-drug interaction (DDI) is a pharmacokinetic or pharmacological influence of 1 medication on another that differs from the known or anticipated effects of each agent alone.1 A DDI may result in a change in either drug efficacy or drug toxicity for 1 or both of the interacting medications.2 Pharmacokinetic DDIs result in altered absorption, distribution, metabolism, or excretion of a medication. [] Key Method Interpreting this information …

Tables from this paper

Drug-Drug Interactions in Acute Coronary Syndrome Patients: Systematic Review
It was showed that ACS patients can be exposed to a variety of DDIs with diverse outcomes which include decreased efficacy of antiplatelet drugs, thrombolytics or anticoagulants, increased risk of bleeding, rhabdomyolysis, hepatotoxicity, adverse effects on cardiovascular system and drug-induced fever.
Monitoring Adverse Drug Reactions and Incidence of Potential Statin-Drug Interactions
Hydroxymethylglutaryl-CoA reductase inhibitors (known as statins) are widely used as lipid-lowering drugs which are considerably elevated in combination with other drugs.
Statin drug interactions and related adverse reactions: an update
A better understanding of the incidence and clinical significance of statin DDIs will help physicians in fine-tuning the lipid-lowering therapeutic interventions thus providing their patients with an evidence-based, safe and cost-effective clinical support.
A Brief Drug Class Review: Considerations for Statin Use, Toxicity, and Drug Interactions
  • J. Wooten
  • Medicine, Biology
    Southern medical journal
  • 2018
P Practitioners who care for patients receiving statins should understand the pharmacologic differences among these drugs, as well as the varied drug interaction potential that all statins possess.
Drug Interactions
Revisiting CYP2C9-Mediated drug-drug Interactions: A Review
Various data regarding CYP2C9 related DDI from in vitro, in vivo and clinical studies were critically discussed in this review to provide insights on how these drugs and natural products may exhibit drug interactions clinically.
Factors associated with clinically relevant drug-drug interactions with statins in outpatients with coronary artery disease
The identification of factors associated with drug interactions allows directing measures to prevent adverse events in more exposed populations, such as those with multiple comorbidities, as well as directing measures for prevenção of eventos adversos em populações mais expostas, como aquelas com múltiplasComorbidades.
Potential statin drug interactions in elderly patients: a review
A better and more close attention to the potential DDIs among statins and other therapeutic options will help physicians in selecting the more effective and less harmful treatment for their patients.
Drug Interactions Affecting Oral Anticoagulant Use
DDI for warfarin mainly involve moderate to strong inhibitors/inducers of cytochrome P450 (CYP) 2C9, which is responsible for the elimination of the more potent S-isomer of warfar in patients with atrial fibrillation and other cardiovascular conditions.


Understanding the Critical Disposition Pathways of Statins to Assess Drug–Drug Interaction Risk During Drug Development: It's Not Just About OATP1B1
This review identifies pathways that contribute the most to, and are therefore the most critical to, the disposition of each statin and proposes in vitro inhibition studies that should be routinely conducted during drug development so as to better assess DDI risk.
Pharmacokinetic-Pharmacodynamic Drug Interactions with HMG-CoA Reductase Inhibitors
Rhabdomyolysis has occurred following the coadministration of cyclosporin, a potent CYP3A4 and P-glycoprotein inhibitor, and lovastatin, and the patient should be monitored for signs and symptoms of myopathy and the statin should be discontinued if necessary.
Safety considerations with fibrate therapy.
Potential statin-drug interactions: prevalence and clinical significance
Although they do not differ between outpatient and inpatient settings, new hazardous coprescriptions are more frequently generated in hospital, and Caution is required when acenocoumarol is coprescribed with statins, especially simvastatin.
Safety review of combination drugs for hyperlipidemia
  • M. Farnier
  • Medicine
    Expert opinion on drug safety
  • 2011
The existing data suggest that ezetimibe, bile acid sequestrants and ω-3 fatty acids appear unlikely to increase the risk of adverse events, particularly myopathy, when used in combination with a statin, even with a high-dose statin.
Multiple drug interactions in a renal transplant patient leading to simvastatin-induced rhabdomyolysis: a case report.
  • S. Rifkin
  • Medicine
    Medscape journal of medicine
  • 2008
A patient with a 12-year history of simvastatin use who presented with rhabdomyolysis, who had a renal transplant and has been on a stable dose of cyclosporine for the past year, is reported.
Drug therapy in the heart transplant recipient: part IV: drug-drug interactions.
An overview of the mechanisms of common and important potential drug–drug interactions and guidelines for avoiding these interactions is provided.
Adherence to Drug Label Recommendations for Avoiding Drug Interactions Causing Statin-Induced Myopathy–A Nationwide Register Study
Prescribers may to some extent avoid co-prescription of statins with calcium blockers and fibrates with an increased risk of myopathy, but there is no evidence for avoiding co-Prescriptions ofstatins and antibiotics with an increase risk of statin-induced adverse drug reactions.
Oral Anticoagulant Drug Interactions with Statins: Case Report of Fluvastatin and Review of the Literature
Clinicians should monitor the INR closely after starting statin therapy inAny patient receiving anticoagulation therapy in any patient receivingAnticoagulant therapy.